Manufacturing Changes Pose Challenges for Biogenerics, Expert Says

Drug Industry Daily
KEYWORDS FDA / generic

One potential problem with making follow-on biologics is that there isn’t enough data to show how changes in manufacturing processes might affect a product’s safety and efficacy, one expert said during a regulatory affairs conference in Baltimore.

To View This Article:


Subscribe To Drug Industry Daily